Uncovering the complexities of neurobiology and neurodegenerative disease requires a robust and yet simple platform for biological testing. xMAP® Technology enables the screening of multiple protein biomarkers from as little as 50 µL of Cerebral Spinal Fluid (CSF), 12 µl of serum, or 15 ng of tissue homogenate, yielding sensitivity in the low picogram per milliliter levels.